ICU · XBRL financial data

SeaStar Medical Holding financial statements, every fiscal year

The same tables from 5 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ICU's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	—	0	135	1,234
Cost of goods and services sold	—	—	0	0	53
Gross profit	—	—	0	135	1,181
Research and development	2,766	2,819	5,973	9,105	7,518
General and administrative	1,122	6,600	8,237	8,872	5,838
Total operating expenses	4,449	11,609	14,210	17,977	13,356
Operating income (loss)	(1,122)	(11,609)	(14,210)	(17,842)	(12,175)
Interest income	12	—	0	101	325
Interest expense	212	630	1,081	244	31
Other income (expense)	(148)	(11,403)	(12,022)	(6,985)	—
Income tax expense (benefit)	(1)	1	0	3	3
Net income (loss)	75	(23,013)	(26,232)	(24,830)	(12,150)
Earnings per share, basic‡ USD per share	(15.75)	(70.00)	(30.25)	(6.63)	(5.86)
Earnings per share, diluted‡ USD per share	(15.75)	(70.00)	(30.25)	(6.63)	—
Weighted average shares, basic‡ thousands of shares	290	328	867	3,744	2,073
Weighted average shares, diluted‡ thousands of shares	290	328	867	3,744	—

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (June 2024); filings made before it reported them unadjusted.

Fiscal years (ICU's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	52	47	176	1,819	11,980
Accounts receivable	—	—	0	112	237
Inventory	—	—	—	0	66
Total current assets	601	3,036	2,308	3,766	13,580
Total assets	105,934	4,767	3,513	4,658	14,158
Accounts payable	85	1,927	4,372	3,046	948
Accrued liabilities	186	2,245	1,523	3,188	2,268
Current portion of long-term debt	—	1,178	565	574	—
Total current liabilities	377	5,350	13,046	6,841	3,742
Total liabilities	10,930	13,002	17,383	6,841	3,742
Accumulated deficit	(10,566)	(99,325)	(114,734)	(139,564)	(151,714)
Total stockholders' equity	(10,566)	(8,235)	(13,870)	(2,183)	10,416
Total liabilities and equity	105,934	4,767	3,513	4,658	14,158
Common shares outstanding (cover page)‡ thousands of shares	—	532	3,017	8,721	3,994

‡ Per-share figures and share counts are adjusted for the 1-for-25 stock split (June 2024); filings made before it reported them unadjusted.

Fiscal years (ICU's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	75	(23,013)	(26,232)	(24,830)	(12,150)
Stock-based compensation	—	1,311	1,930	887	624
Net cash from operating activities	(1,170)	(7,794)	(10,285)	(16,007)	(13,599)
Net cash from investing activities	(105,570)	—	—	—	—
Proceeds from issuing common stock	—	0	4,742	17,441	16,126
Proceeds from long-term debt	—	—	—	1,087	—
Net cash from financing activities	106,753	7,331	10,414	17,650	23,760
Net change in cash	—	—	—	1,643	10,161

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
SeaStar Medical Holding	6,959	615	(2,994)*	4.4M	2.3 quarters	Q2 FY26 10-QJun 30, 2026
ENvue Medical	1,084	239	(2,691)*	11.1M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
Tenon Medical	1,677	1,279	(2,758)*	667,047	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Bone Biologics	6,088	not reported	(532)*	3.4M	9.8 quarters	Q3 FY26 10-QSep 30, 2026
Sintx Technologies	3,590	452	(2,767)*	6.7M	1.3 quarters	Q2 FY26 10-QJun 30, 2026
OSR Health	1,500	316	(2,421)*	35.1M	0.6 quarters	Q2 FY26 10-QJun 30, 2026
Adm Tronics Unlimited	223	not reported	(33)	67.6M	6.8 quarters	Q1 FY26 10-QJun 30, 2026
Retractable Technologies	2,641	7,201	(1,732)*	29.9M	1.5 quarters	Q2 FY26 10-QJun 30, 2026
Sonoma Pharmaceuticals	5,338	6,406	(649)	4.8M	8.2 quarters	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.